Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases

被引:77
|
作者
Dinkelacker, V [1 ]
Dietl, T [1 ]
Widman, G [1 ]
Lengler, U [1 ]
Elger, CE [1 ]
机构
[1] Univ Bonn, Ctr Med, Dept Epileptol, D-53105 Bonn, Germany
关键词
epilepsy; levetiracetam; antiepileptic drugs; aggression; irritability; behavioral adverse effect;
D O I
10.1016/j.yebeh.2003.07.008
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Levetiracetam (LEV) was shown to be very efficacious and well tolerated as add-on therapy for refractory epilepsy. Here we report 33 patients with longstanding histories of epilepsy who experienced aggressive episodes during LEV therapy. This corresponds to 3.5% of LEV-treated patients as compared with less than 1% of patients not on LEV. Among these cases, 24 showed only moderate, partly transient irritability, with 10 patients requiring reduction or discontinuation of LEV. More strikingly, 9 patients displayed severe symptoms of aggression with physical violence and, in 2 cases, the need for psychiatric emergency treatment. One patient developed additional psychotic symptoms. We suggest that, specifically in patients with a previous history of aggression, behavioral tolerability of LEV should be carefully monitored. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:537 / 547
页数:11
相关论文
共 41 条
  • [1] Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy
    Ben-Menachem, E
    Edrich, P
    Van Vleymen, B
    Sander, JWA
    Schmidt, B
    EPILEPSY RESEARCH, 2003, 53 (1-2) : 57 - 64
  • [2] Utility of levetiracetam as and add-on therapy Mexican patients with refractory epilepsy
    Edith, Alva-Moncayo
    Claudia, Sainos-Ramirez
    Francisco Javier, Rogel-Ortiz
    Ruben, Garcia-Garcia
    Enrique, Garcia-Cuevas
    Hugo, Ceja
    Amado Francisco, Rodriguez
    REVISTA MEXICANA DE NEUROCIENCIA, 2011, 12 (03): : 128 - 133
  • [3] Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy
    Lucie Blais
    Odile Sheehy
    Jean-Marc Saint-Hilaire
    Gilles-Pierre Bernier
    Philippe Godfroid
    Jacques LeLorier
    PharmacoEconomics, 2005, 23 : 493 - 503
  • [4] Levetiracetam add-on therapy in Japanese patients with refractory partial epilepsy
    Tanaka, Shigeya
    Tanaka, Tatsuya
    EPILEPTIC DISORDERS, 2013, 15 (02) : 132 - 141
  • [5] The efficacy and tolerability of Levetiracetam as an add-on therapy in patients with startle epilepsy
    Gurses, Candan
    Alpay, Kadriye
    Ciftci, Farah Diba
    Bebek, Nerses
    Baykan, Betuel
    Gokyigit, Aysen
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2008, 17 (07): : 625 - 630
  • [6] Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add-on therapy compared to levetiracetam and valproic acid
    Liguori, Claudio
    Turner, Katherine
    Izzi, Francesca
    Assogna, Martina
    Canevini, Maria P.
    Mercuri, Nicola B.
    Placidi, Fabio
    CNS NEUROSCIENCE & THERAPEUTICS, 2019, 25 (05) : 632 - 637
  • [7] The clinical efficacy and safety of levetiracetam add-on therapy for child refractory epilepsy
    Chen, J.
    Liu, X. -M.
    Yue, X.
    Chen, S. -Z.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2016, 20 (12) : 2689 - 2694
  • [8] Efficacy of levetiracetam as first add-on therapy to carbamazepine and valproate sodium for children with epilepsy
    Kanemura, Hideaki
    Sano, Fumikazu
    Ohyama, Tetsuo
    Sugita, Kanji
    Aihara, Masao
    JOURNAL OF PEDIATRIC EPILEPSY, 2014, 3 (02) : 77 - 83
  • [9] Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial
    Lagae, L
    Buyse, G
    Ceulemans, B
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2005, 14 (01): : 66 - 71
  • [10] Role of high-dose levetiracetam as add-on therapy for intractable epilepsy: case report and brief review of the literature
    Hector Mateo-Carrasco
    Pedro Jesús Serrano-Castro
    Emilio Molina-Cuadrado
    Mel Goodwin
    Timothy V. Nguyen
    Primal N. Kotecha
    International Journal of Clinical Pharmacy, 2015, 37 : 559 - 562